CD8A and neoplasm: ICB therapies recover the cytotoxic potential of CD8+ T cells with antigen receptors (T-cell receptors, TCRs) that recognize tumour-derived peptides bound to major histocompatibility complex (MHC) molecules on tumour cells and enable cytotoxic T cells to eliminate tumour cells anywhere in the organism.